ArticleAbdominal radiology (New York)2026
Baseline CT imaging features combined with clinical indicators predict prognosis in unresectable HCC treated with HAIC plus targeted therapy and immunotherapy.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the prognostic value of baseline contrast-enhanced CT features imaging combined with clinical indicators in patients with unresectable hepatocellular carcinoma (uHCC) treated with hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy (HAIC-TI).
methodsPatients with uHCC who received at least two cycles of HAIC-TI were retrospectively analyzed. Inclusion required pre-treatment contrast-enhanced CT and modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessments after two HAIC-TI cycles. Patients were classified into progressive disease (PD) group and non-PD group (complete response [CR], partial response [PR], or stable disease [SD]) to identify predictors of early progression. Baseline predictors of early progression were identified using binary logistic regression analysis. For survival analysis, the patients were reclassified into the responder group (CR or PR) and the non-responder group (SD or PD). Overall survival (OS) was estimated using the Kaplan-Meier method and compared by log-rank test. Prognostic factors for OS were identified using Cox regression.
resultsA total of 132 patients were included in this study. The objective response rate (ORR) was 47.7% and disease control rate (DCR) was 86.4% based on mRECIST criteria. The median progression free survival (PFS) was significantly prolonged in the responder group compared to the non-responder group (29.6 months vs. 8.0 months, p < 0.001). Correspondingly, the median OS was longer in the responder group (not reached) than in the non-responder group (10.5 months) (p < 0.001). Non-peripheral washout on baseline CT was associated with a lower risk of early progression (odds ratio = 0.280, p = 0.027). Multivariate analysis identified satellite nodules (hazard ratio [HR] = 2.419, p = 0.002), prolonged prothrombin time(HR = 1.930, p = 0.009), Child-Pugh class B (HR = 2.346, p = 0.009), and unfavorable early treatment response (HR = 2.478, p < 0.001) as independent predictors of shorter OS, while more HAIC-TI cycles (HR = 0.505, p = 0.010) were associated with longer OS. Further subgroup analysis revealed that the number of HAIC sessions was not statistically significant in the responder group (p = 0.27), nor in non-responder group (p = 0.34).
conclusionsFor patients with non-peripheral washout pattern in the delayed phase on imaging, the HAIC-TI treatment represents a feasible therapeutic strategy. It is noteworthy that early treatment responders showed significantly superior survival prognosis, whereas non-responders did not attain meaningful survival advantages despite receiving additional HAIC treatment cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.